Robert Hoit, MD
Nephrology · Montgomery, ALNPI 1285638247
Payments from drug & device makers
Across 44 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$162
- OPKO Pharmaceuticals, LLC$153
- Amgen$122
- Akebia Therapeutics Inc$96
- Fresenius USA Marketing, Inc.$92
- Otsuka America Pharmaceutical, Inc.$61
- plus $173 from 7 others
What the payments were for
- Food & beverage$81595%
- Education$455%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 7 | $162 |
| OPKO Pharmaceuticals, LLC | 9 | $153 |
| Amgen(2 entities) | 6 | $122 |
| Akebia Therapeutics Inc | 4 | $96 |
| Fresenius USA Marketing, Inc. | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Lilly USA, LLC | 3 | $55 |
| Aurinia Pharma U.S., Inc. | 2 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| GSK | 1 | $17 |
| Bayer | 1 | $17 |
| Novo Nordisk | 1 | $16 |
How this compares
$860 in reported general payments places this provider in the 30th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 12 | $7,726 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $5,709 |
| Calcitriol | 221 | $4,668 |
| Losartan Potassium | 152 | $1,496 |
| Bumetanide | 27 | $1,402 |
| Amlodipine Besylate | 122 | $981 |
| Hydralazine Hcl | 44 | $897 |
| Lisinopril | 67 | $696 |
| Carvedilol | 55 | $694 |
| Nifedipine ErNifedipine | 17 | $682 |
| Mycophenolate Mofetil | 19 | $663 |
| Spironolactone | 42 | $567 |
| Chlorthalidone | 23 | $534 |
| Furosemide | 83 | $490 |
| Metoprolol Succinate | 17 | $468 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Montgomery
- Sumeet MunjalMontgomery$191K
- Rafael LopezMontgomery$6K
- Kim McGlothanMontgomery$5K
- David TietjenHuntsville$2.6M
- Dana RizkBirmingham$2.6M
- Michael QuadriniHuntsville$1.3M
- Eric WallaceBirmingham$1.3M
- David BainsHuntsville$856K
- Michal MrugBirmingham$793K
- Phillip MadoniaAlabaster$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.